Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
11
BPTH Quote, Financials, Valuation and Earnings
Last price:
$0.16
Seasonality move
:
5.23%
Day range:
$0.16 - $0.17
52-week range:
$0.12 - $3.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
9.98x
Volume:
32.4K
Avg. volume:
44.7K
1-year change:
-91.81%
Market cap:
$1.3M
Revenue:
--
EPS (TTM):
-$2.74
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Bio-Path Holdings has 1165.82% upside to fair value with a price target of $2.00 per share.
BPTH vs. S&P 500
-
Over the past 5 trading days, Bio-Path Holdings has underperformed the S&P 500 by -3.41% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bio-Path Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bio-Path Holdings has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Bio-Path Holdings reported revenues of --.
Earnings Growth
-
Bio-Path Holdings has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Bio-Path Holdings reported earnings per share of -$0.40.
Enterprise value:
1.4M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.13x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$15.8M | -$14.2M | -$11.5M | -$3.7M | -$3.2M | |
| EBITDA | -$15.7M | -$13.5M | -$11M | -$3.1M | -$2.8M | |
| Diluted EPS | -$41.97 | -$26.17 | -$2.74 | -$4.88 | -$0.40 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $32.6M | $23.6M | $10.8M | $1.6M | $2.1M | |
| Total Assets | $33.1M | $24.1M | $11.1M | $1.8M | $2.2M | |
| Current Liabilities | $1.5M | $1.6M | $1.9M | $3.8M | $4.7M | |
| Total Liabilities | $1.7M | $1.8M | $2M | $4.4M | $4.8M | |
| Total Equity | $31.4M | $22.3M | $9.1M | -$2.6M | -$2.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$16.2M | -$8.9M | -$10.9M | -$1M | -$1.3M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | $2.4M | $10.8M | $174K | $262K | |
| Free Cash Flow | -$16.2M | -$8.9M | -$10.9M | -$1M | -$1.3M | |
BPTH
Sector
Market Cap
$1.3M
$34.4M
Price % of 52-Week High
4.66%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-91.81%
-37.36%
Beta (5-Year)
-0.032
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.16
200-day SMA
Sell
Level
$0.53
Bollinger Bands (100)
Sell
Level
0.15 - 0.19
Chaikin Money Flow
Sell
Level
-460.9M
20-day SMA
Sell
Level
$0.17
Relative Strength Index (RSI14)
Sell
Level
42.54
ADX Line
Buy
Level
19.57
Williams %R
Buy
Level
-92.7536
50-day SMA
Sell
Level
$0.18
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
821.7M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Stock Forecast FAQ
In the current month, BPTH has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BPTH average analyst price target in the past 3 months is $2.00.
-
Where Will Bio-Path Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bio-Path Holdings share price will rise to $2.00 per share over the next 12 months.
-
What Do Analysts Say About Bio-Path Holdings?
Analysts are divided on their view about Bio-Path Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bio-Path Holdings is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Bio-Path Holdings's Price Target?
The price target for Bio-Path Holdings over the next 1-year time period is forecast to be $2.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BPTH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bio-Path Holdings is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BPTH?
You can purchase shares of Bio-Path Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bio-Path Holdings shares.
-
What Is The Bio-Path Holdings Share Price Today?
Bio-Path Holdings was last trading at $0.16 per share. This represents the most recent stock quote for Bio-Path Holdings. Yesterday, Bio-Path Holdings closed at $0.16 per share.
-
How To Buy Bio-Path Holdings Stock Online?
In order to purchase Bio-Path Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
72
SBET alert for Jul 18
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 19.81% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 17.85% over the past day.
